Lenalidomide Exposure and TP53-Mutated Myelodysplastic Syndromes/Neoplasms.

Katamesh B, Shallis RM

Open source

DOI
10.3390/curroncol33090506
Published
2026 Aug 26
Container
Current oncology (Toronto, Ont.)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/curroncol33090506,
  title = {Lenalidomide Exposure and TP53-Mutated Myelodysplastic Syndromes/Neoplasms.},
  author = {Katamesh B and Shallis RM},
  year = {2026},
  journal = {Current oncology (Toronto, Ont.)},
  doi = {10.3390/curroncol33090506},
  url = {https://doi.org/10.3390/curroncol33090506}
}

RIS

TY  - JOUR
TI  - Lenalidomide Exposure and TP53-Mutated Myelodysplastic Syndromes/Neoplasms.
AU  - Katamesh B
AU  - Shallis RM
PY  - 2026
JO  - Current oncology (Toronto, Ont.)
DO  - 10.3390/curroncol33090506
UR  - https://doi.org/10.3390/curroncol33090506
ER  - 

APA

B, K., & RM, S. (2026). Lenalidomide Exposure and TP53-Mutated Myelodysplastic Syndromes/Neoplasms.. Current oncology (Toronto, Ont.). https://doi.org/10.3390/curroncol33090506

Source records